• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Hyperparathyroidism

Hyperparathyroidism - 63 Studies Found

Active, not recruiting : To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
: Hyperparathyroidism, Secondary
: 2014-03-03
: Drug: AMG 416 Subjects will be administered IV AMG 416 at the end of their regular dialysis sessions on
Completed : Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
: Secondary Hyperparathyroidism
: 2010-12-03
:
  • Drug: Etelcalcetide Administer

Completed : Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT)
: Secondary Hyperparathyroidism
: 2009-01-22
:
  • Drug: 1.0 μg/day Alfacalcidol

Completed : Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients
: Secondary Hyperparathyroidism
: 2015-01-11
: Drug: Combination Cinacalcet with Vitamin D analogue Depending on the iPTH level and the serum calcium l
Completed : LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients
: Secondary Hyperparathyroidism
: 2010-07-02
: Drug: LEO 27847 First in patient
Completed : Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation
: Secondary Hyperparathyroidism
: 2010-04-19
:
  • Procedure: Subtotal parathyroidectomy

Completed : A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism
: Secondary Hyperparathyroidism
: 2012-07-25
: Drug: DP001 DP001 softgel capsules; 55 ng to 550 ng per dose, administered 3 times weekly for 4 weeks
Completed : Optimal Anemia Treatment in End Stage Renal Disease (ERSD)
: Hyperparathyroidism, Secondary
: 2014-06-27
:
  • Drug: standard care Standard c

Terminated : Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism
: Secondary Hyperparathyroidism
: 2012-04-05
: Drug: Etelcalcetide Administered as an intravenous bolus three times a week at the end of each hemodialy
Completed : ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism
: Secondary Hyperparathyroidism
: 2005-08-24
:
  • Drug: Sensipar® Cinacalce

<<< Previous | Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.